PL3303583T3 - Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym - Google Patents
Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznymInfo
- Publication number
- PL3303583T3 PL3303583T3 PL16729807T PL16729807T PL3303583T3 PL 3303583 T3 PL3303583 T3 PL 3303583T3 PL 16729807 T PL16729807 T PL 16729807T PL 16729807 T PL16729807 T PL 16729807T PL 3303583 T3 PL3303583 T3 PL 3303583T3
- Authority
- PL
- Poland
- Prior art keywords
- producing
- flow filtration
- tangential flow
- purifying rna
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/08—Polysaccharides
- B01D71/12—Cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Water Supply & Treatment (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015062002 | 2015-05-29 | ||
| PCT/EP2016/062152 WO2016193206A1 (en) | 2015-05-29 | 2016-05-30 | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
| EP16729807.4A EP3303583B1 (en) | 2015-05-29 | 2016-05-30 | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3303583T3 true PL3303583T3 (pl) | 2020-10-19 |
Family
ID=53385598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16729807T PL3303583T3 (pl) | 2015-05-29 | 2016-05-30 | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
| PL22190069.9T PL4108769T3 (pl) | 2015-05-29 | 2016-05-30 | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22190069.9T PL4108769T3 (pl) | 2015-05-29 | 2016-05-30 | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US10760070B2 (pl) |
| EP (3) | EP3744843A1 (pl) |
| CN (2) | CN107873055B (pl) |
| DE (2) | DE202016009003U1 (pl) |
| DK (2) | DK4108769T3 (pl) |
| ES (2) | ES2798271T3 (pl) |
| PL (2) | PL3303583T3 (pl) |
| PT (2) | PT3303583T (pl) |
| WO (1) | WO2016193206A1 (pl) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| EP3590529A1 (en) | 2014-03-12 | 2020-01-08 | CureVac AG | Combination of vaccination and ox40 agonists |
| EP3636742A1 (en) | 2014-04-25 | 2020-04-15 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US11149278B2 (en) | 2014-12-12 | 2021-10-19 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
| US10653768B2 (en) | 2015-04-13 | 2020-05-19 | Curevac Real Estate Gmbh | Method for producing RNA compositions |
| EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
| JP6893177B2 (ja) | 2015-05-15 | 2021-06-23 | キュアバック アーゲー | 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ） |
| EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
| SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
| EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| DE202016009003U1 (de) * | 2015-05-29 | 2021-05-28 | Curevac Real Estate Gmbh | Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration |
| WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
| SG10201913629VA (en) | 2015-08-28 | 2020-03-30 | Curevac Ag | Artificial nucleic acid molecules |
| EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| WO2017140905A1 (en) | 2016-02-17 | 2017-08-24 | Curevac Ag | Zika virus vaccine |
| WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
| KR102378404B1 (ko) * | 2016-04-22 | 2022-03-24 | 비온테크 에스이 | 단일가닥 rna 제공 방법 |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| EP3452493B1 (en) | 2016-05-04 | 2025-01-15 | CureVac SE | Nucleic acid molecules and uses thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| KR20190029576A (ko) | 2016-06-09 | 2019-03-20 | 큐어백 아게 | 핵산 카고용 하이브리드 담체 |
| WO2018041921A1 (en) | 2016-08-31 | 2018-03-08 | Curevac Ag | Mixing device for the production of a liquid nucleic acid composition |
| US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| EP3808380A1 (en) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
| EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
| ES2925083T3 (es) | 2017-02-27 | 2022-10-13 | Translate Bio Inc | Métodos de purificación de ARN mensajero |
| JP2020514370A (ja) | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤 |
| EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| ES2906158T3 (es) | 2017-05-01 | 2022-04-13 | Meda Pharma Gmbh & Co Kg | Proceso para convertir ascomicina bruta en pimecrolimus purificado |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| CN110997117B (zh) * | 2017-06-30 | 2023-08-01 | 戴弗西公司 | 膜清洁溶液和使用其加速膜清洁的方法 |
| WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | NEW NUCLEIC ACID MOLECULES |
| EP3668979A4 (en) * | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | Methods for hplc analysis |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
| SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
| US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
| SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| DE202019006108U1 (de) | 2018-04-17 | 2024-12-16 | CureVac SE | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung |
| EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
| AU2019293714C1 (en) | 2018-06-28 | 2023-09-21 | CureVac Manufacturing GmbH | Bioreactor for RNA in vitro transcription |
| CN112955239B (zh) * | 2018-07-27 | 2022-11-29 | 沃特世科技公司 | 用于极性分子分析的液相色谱/质谱方法 |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US11241656B2 (en) * | 2018-11-29 | 2022-02-08 | Watersep Bioseparations Llc | Single pass cross flow diafiltration module and method |
| WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
| US20220098574A1 (en) * | 2019-01-29 | 2022-03-31 | Flagship Pioneering Innovations V, Inc. | Methods of separating long polynucleotides from a composition |
| MX2021009169A (es) | 2019-02-11 | 2021-10-13 | Ethris Gmbh | Purificacion de arnm por filtracion de flujo tangencial. |
| WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
| US20220306678A1 (en) * | 2019-06-20 | 2022-09-29 | Arcturus Therapeutics, Inc. | Improved in vitro transcription purification platform |
| CN114502204A (zh) | 2019-08-14 | 2022-05-13 | 库尔维科公司 | 具有降低的免疫刺激性质的rna组合和组合物 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| EP4147717A1 (en) | 2020-02-04 | 2023-03-15 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US20230116671A1 (en) * | 2020-02-21 | 2023-04-13 | Biogen Ma Inc. | Methods of preparing oligonucleotide compositions using ultrafiltration/diafiltration |
| AU2021261471B2 (en) | 2020-04-22 | 2024-10-24 | BioNTech SE | Coronavirus vaccine |
| WO2021229217A1 (en) * | 2020-05-12 | 2021-11-18 | Cranfield University | A method and modular apparatus for the synthesis of rna-based therapeutics |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| US20240246056A1 (en) | 2020-09-01 | 2024-07-25 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| EP4243966A1 (en) | 2020-11-23 | 2023-09-20 | Abec, Inc. | Filtration systems,components and methods |
| EP4251323A1 (en) | 2020-11-27 | 2023-10-04 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
| US20240299309A1 (en) | 2020-12-22 | 2024-09-12 | CureVac SE | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | Glaxosmithkline Biologicals Sa | Rna vaccine against sars-cov-2 variants |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| CA3170747A1 (en) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
| WO2022231661A1 (en) * | 2021-04-30 | 2022-11-03 | Hydranautics | Concentration and diafiltration of oligonucleotides |
| KR20240047986A (ko) * | 2021-07-27 | 2024-04-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 가공을 위한 디바이스, 시스템 및 방법 |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| EP4482956A1 (en) * | 2022-02-25 | 2025-01-01 | Amgen Inc. | Methods of preparing high concentration liquid drug substances |
| EP4504252A2 (en) | 2022-04-08 | 2025-02-12 | Flagship Pioneering Innovations VII, LLC | Vaccines and related methods |
| CN114921457B (zh) * | 2022-05-16 | 2023-09-29 | 硅羿科技（上海）有限公司 | 一种提取dsRNA的方法 |
| WO2023225524A1 (en) * | 2022-05-17 | 2023-11-23 | Modernatx, Inc. | Preparation of highly concentrated mrna |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024023335A1 (en) * | 2022-07-29 | 2024-02-01 | Sanofi | Methods for ethanol-free mrna purification |
| WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024194767A1 (en) | 2023-03-17 | 2024-09-26 | BioNTech SE | Automated drug production system |
| WO2024199650A1 (de) * | 2023-03-29 | 2024-10-03 | Wacker Chemie Ag | Crispr-cas9 basierte linearisierung von plasmid dna-templaten |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024235451A1 (en) | 2023-05-16 | 2024-11-21 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2024245907A1 (en) | 2023-05-26 | 2024-12-05 | CureVac SE | Cancer antigens |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2024260570A1 (en) | 2023-06-23 | 2024-12-26 | CureVac SE | Nucleic acid encoded antibodies |
| WO2025027060A1 (en) | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025027116A1 (en) | 2023-08-01 | 2025-02-06 | Institut Curie | Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase |
| WO2025036992A1 (en) | 2023-08-16 | 2025-02-20 | CureVac SE | Rna conjugates |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (197)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839295A (en) | 1984-06-08 | 1989-06-13 | Pierce Chemical Company | Measurement of protein using bicinchoninic acid |
| DE3639949A1 (de) | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | Verfahren zur trennung von langkettigen nukleinsaeuren |
| CA2033718A1 (en) | 1990-01-19 | 1991-07-20 | Ronald M. Atlas | Process for detection of water-borne microbial pathogens and indicators of human fecal contamination in water samples and kits therefor |
| US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
| AU7839594A (en) | 1993-09-20 | 1995-04-10 | Regents Of The University Of Colorado, The | Strategy for the production of rna from immobilized templates |
| CA2468048A1 (en) | 1994-02-23 | 1995-08-31 | Pamela Pavco | Process for purifying chemically synthesized rna |
| US5447922A (en) | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7807822B2 (en) | 1996-08-01 | 2010-10-05 | Robert Bridenbaugh | Methods for purifying nucleic acids |
| US6011148A (en) | 1996-08-01 | 2000-01-04 | Megabios Corporation | Methods for purifying nucleic acids |
| US5849546A (en) | 1996-09-13 | 1998-12-15 | Epicentre Technologies Corporation | Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP0853123A1 (de) * | 1997-01-10 | 1998-07-15 | Roche Diagnostics GmbH | Reinigung von DNA durch Cross-Flow-Filtration |
| JP4196236B2 (ja) | 1998-03-17 | 2008-12-17 | 東洋紡績株式会社 | 核酸増幅用試薬および配列特異的な核酸増幅法 |
| US20020102563A1 (en) | 1998-04-24 | 2002-08-01 | Gjerde Douglas T. | Apparatus and method for separating and purifying polynucleotides |
| US6780327B1 (en) | 1999-02-25 | 2004-08-24 | Pall Corporation | Positively charged membrane |
| ATE347616T1 (de) | 1999-04-30 | 2006-12-15 | Cyclops Genome Sciences Ltd | Ribonukleinsäurederivate |
| US20020010145A1 (en) | 1999-07-12 | 2002-01-24 | Willson Richard C. | Apparatus, methods and compositions for biotechnical separations |
| HUP0202295A3 (en) * | 1999-07-23 | 2005-01-28 | Genentech Inc | Method for rnase- and organic solvent-free plasmid dna purification using tangential flow filtration |
| JP2004506873A (ja) | 1999-12-22 | 2004-03-04 | トランスジエノミツク・インコーポレーテツド | 自動化マッチトイオンポリヌクレオチドクロマトグラフィーのための系および方法 |
| US6773885B1 (en) | 2000-09-29 | 2004-08-10 | Integrated Dna Technologies, Inc. | Compositions and methods for visual ribonuclease detection assays |
| GB0028361D0 (en) | 2000-11-21 | 2001-01-03 | Glaxo Group Ltd | Method of separating extra chromosomal dna from other cellular components |
| US7074333B2 (en) * | 2001-01-19 | 2006-07-11 | Millipore Corporation | Recovery of linear nucleic acids by salt dilution and/or reduced pressure prior to continuous pressure differential ultrafiltration |
| GB0107634D0 (en) | 2001-03-27 | 2001-05-16 | Fermentas Ab | Nucleic acid purification |
| DE50211110D1 (de) | 2001-04-21 | 2007-12-06 | Curevac Gmbh | INJEKTIONSGERÄT FÜR mRNA APPLIKATION |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US6989442B2 (en) | 2002-07-12 | 2006-01-24 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
| US7655790B2 (en) | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
| DE10240868A1 (de) | 2002-09-04 | 2004-03-18 | Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH | Verbesserte Verfahren zur Synthese von Nukleinsäuren |
| EP1601788A4 (en) | 2003-02-24 | 2006-11-15 | Gtc Biotherapeutics Inc | METHOD OF TANGENTIAL ELECTRIC FILTRATION AND DEVICE THEREFOR |
| WO2004081033A2 (en) | 2003-03-11 | 2004-09-23 | National Institutes Of Health | Synthesis of proteins by cell-free protein expression |
| US7125492B2 (en) | 2003-07-17 | 2006-10-24 | Agilent Technologies, Inc. | Additives for reversed-phase HPLC mobile phases |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| US8075780B2 (en) | 2003-11-24 | 2011-12-13 | Millipore Corporation | Purification and concentration of synthetic biological molecules |
| ATE466080T1 (de) | 2003-12-16 | 2010-05-15 | Qiagen North American Holdings | Formulierungen und verfahren zum denaturieren von proteinen |
| US20050287539A1 (en) | 2004-06-29 | 2005-12-29 | Emmanuel Labourier | Methods and compositions for preparing capped RNA |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| DE502005008794D1 (de) | 2004-08-03 | 2010-02-11 | Geneart Ag | Verfahren zur modulation der genexpression durch änderung des cpg gehalts |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| ATE464381T1 (de) | 2004-12-23 | 2010-04-15 | Ge Healthcare Bio Sciences | Rna-amplifikation auf ligationsbasis |
| CN101310022B (zh) * | 2005-01-31 | 2013-01-16 | 默沙东公司 | 大规模生产质粒dna的上游和下游纯化方法 |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP1960550B1 (en) | 2005-12-12 | 2010-09-15 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Probe for nucleic acid sequencing and methods of use |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| US7781573B2 (en) | 2006-08-03 | 2010-08-24 | Nam Q Ngo | Multi layer chromatography of nucleic acids |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8859229B2 (en) | 2007-02-02 | 2014-10-14 | Yale University | Transient transfection with RNA |
| EP1970441A1 (en) | 2007-03-06 | 2008-09-17 | BioAlliance Pharma | Plasmid containing a sequence encoding a disintegrin domain of metargidin (RDD) |
| CN107501370B (zh) | 2007-06-19 | 2021-06-18 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗-反向硫代磷酸类似物的合成和用途 |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| ES2537703T3 (es) | 2008-01-31 | 2015-06-11 | Curevac Gmbh | Ácidos nucleicos que comprenden la fórmula (NuGlXmGnNv)a y sus derivados como agentes/adyuvantes inmunoestimuladores |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR102178191B1 (ko) | 2008-09-02 | 2020-11-13 | 머크 밀리포어 리미티드 | 크로마토그래피 막, 이를 포함하는 장치 및 이의 이용방법 |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN102712955A (zh) | 2009-11-03 | 2012-10-03 | Htg分子诊断有限公司 | 定量核酸酶保护测序(qNPS) |
| WO2011069528A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| DK2449113T3 (en) | 2010-07-30 | 2016-01-11 | Curevac Ag | Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| PT3590949T (pt) | 2010-10-01 | 2022-08-02 | Modernatx Inc | Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações |
| WO2012077080A1 (en) | 2010-12-10 | 2012-06-14 | Tracy Thompson | Compositions for separation methods |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| KR20190099538A (ko) | 2011-10-03 | 2019-08-27 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
| EP2773326B1 (en) | 2011-11-04 | 2019-02-20 | Nitto Denko Corporation | Method for sterilely producing lipid-nucleic acid particles |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| KR20140139101A (ko) | 2012-03-27 | 2014-12-04 | 큐어백 게엠바하 | 5''top utr을 포함하는 인공 핵산 분자 |
| AU2013242403B2 (en) | 2012-03-27 | 2018-10-18 | Curevac Ag | Artificial nucleic acid molecules |
| CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
| ES2719598T3 (es) | 2012-05-25 | 2019-07-11 | Curevac Ag | Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables) |
| EP3884949A1 (en) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| ES2968649T3 (es) | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
| AU2014238369B2 (en) | 2013-02-14 | 2017-03-02 | Tencate Advanced Armor Design, Inc. | Turret air bags |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| JP6399560B2 (ja) | 2013-03-14 | 2018-10-03 | トランスレイト バイオ， インコーポレイテッド | ｍＲＮＡによってコードされる抗体を送達するための方法及び組成物 |
| EP2970955B1 (en) * | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| EP3578663A1 (en) * | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| EP4279610A3 (en) * | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
| PT2970948T (pt) | 2013-03-15 | 2019-03-20 | Glaxosmithkline Biologicals Sa | Métodos de purificação de arn |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| MX2016002152A (es) | 2013-08-21 | 2017-01-05 | Curevac Ag | Metodo para aumentar la expresion de proteinas codificadas por arn. |
| SG11201510748PA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| CN105517566A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 用于治疗前列腺癌的组合物和疫苗 |
| DE102013111099B4 (de) | 2013-10-08 | 2023-11-30 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
| JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
| SG11201607382TA (en) | 2014-03-07 | 2016-10-28 | Agency Science Tech & Res | Apparatus and methods for fractionation of biological products |
| EP3590529A1 (en) | 2014-03-12 | 2020-01-08 | CureVac AG | Combination of vaccination and ox40 agonists |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| EP3636742A1 (en) | 2014-04-25 | 2020-04-15 | Translate Bio, Inc. | Methods for purification of messenger rna |
| AU2015273933B2 (en) | 2014-06-10 | 2021-02-11 | CureVac Manufacturing GmbH | Methods and means for enhancing RNA production |
| ES2742704T3 (es) | 2014-06-25 | 2020-02-17 | Emd Millipore Corp | Elementos, módulos y sistemas de filtro compactos, enrollados en espiral |
| US11149278B2 (en) | 2014-12-12 | 2021-10-19 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| KR102580696B1 (ko) | 2014-12-30 | 2023-09-19 | 큐어백 에스이 | 신규 인공 핵산 분자 |
| US10653768B2 (en) | 2015-04-13 | 2020-05-19 | Curevac Real Estate Gmbh | Method for producing RNA compositions |
| EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
| MX2017013321A (es) | 2015-04-22 | 2018-07-06 | Curevac Ag | Composicion que contiene arn para tratamiento de enfermedades tumorales. |
| SG11201708681SA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
| JP6893177B2 (ja) | 2015-05-15 | 2021-06-23 | キュアバック アーゲー | 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ） |
| SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
| EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
| DE202016009003U1 (de) | 2015-05-29 | 2021-05-28 | Curevac Real Estate Gmbh | Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration |
| EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| WO2016203025A1 (en) | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
| WO2017001058A1 (en) | 2015-07-01 | 2017-01-05 | Curevac Ag | Method for analysis of an rna molecule |
| WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
| WO2017021546A1 (en) | 2015-08-05 | 2017-02-09 | Curevac Ag | Epidermal mrna vaccine |
| US20190024096A1 (en) | 2015-08-07 | 2019-01-24 | Curevac Ag | Process for the in vivo production of rna in a host cell |
| CN116064623A (zh) | 2015-08-10 | 2023-05-05 | 库瑞瓦格制造业有限公司 | 增加环状dna分子复制的方法 |
| SG10201913629VA (en) | 2015-08-28 | 2020-03-30 | Curevac Ag | Artificial nucleic acid molecules |
| EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| US20180312545A1 (en) | 2015-11-09 | 2018-11-01 | Curevac Ag | Optimized nucleic acid molecules |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| US20180371392A1 (en) | 2015-12-21 | 2018-12-27 | Curevac Ag | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| WO2017137095A1 (en) | 2016-02-12 | 2017-08-17 | Curevac Ag | Method for analyzing rna |
| US20190049414A1 (en) | 2016-02-15 | 2019-02-14 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
| WO2017140905A1 (en) | 2016-02-17 | 2017-08-24 | Curevac Ag | Zika virus vaccine |
| WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
| US20190177714A1 (en) | 2016-03-24 | 2019-06-13 | Curevac Ag | Immobilized inorganic pyrophosphatase (ppase) |
| EP3777881A1 (en) | 2016-04-22 | 2021-02-17 | CureVac AG | Rna encoding a tumor antigen |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| EP3452493B1 (en) | 2016-05-04 | 2025-01-15 | CureVac SE | Nucleic acid molecules and uses thereof |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| US20210162037A1 (en) | 2016-05-04 | 2021-06-03 | Curevac Ag | Influenza mrna vaccines |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| EP3464619A1 (en) | 2016-05-25 | 2019-04-10 | CureVac AG | Novel biomarkers |
| KR20190029576A (ko) | 2016-06-09 | 2019-03-20 | 큐어백 아게 | 핵산 카고용 하이브리드 담체 |
| WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| WO2017212008A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| JP2019526556A (ja) | 2016-08-19 | 2019-09-19 | キュアバック アーゲー | 癌治療用ｒｎａ |
| SG11201903460QA (en) | 2016-10-26 | 2019-05-30 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| EP3808380A1 (en) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
| JP2020514370A (ja) | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤 |
| EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | NEW NUCLEIC ACID MOLECULES |
| EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
| SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
| US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
| SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| DE202019006108U1 (de) | 2018-04-17 | 2024-12-16 | CureVac SE | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung |
| EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
| AU2019293714C1 (en) | 2018-06-28 | 2023-09-21 | CureVac Manufacturing GmbH | Bioreactor for RNA in vitro transcription |
| WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
| US20220073962A1 (en) | 2018-12-21 | 2022-03-10 | Curevac Ag | Methods for rna analysis |
| EP4491229A2 (en) | 2019-02-08 | 2025-01-15 | CureVac SE | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| CA3129248A1 (en) | 2019-02-08 | 2020-08-13 | Board Of Regents, The University Of Texas System | Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
-
2016
- 2016-05-30 DE DE202016009003.9U patent/DE202016009003U1/de not_active Expired - Lifetime
- 2016-05-30 DK DK22190069.9T patent/DK4108769T3/da active
- 2016-05-30 DE DE22190069.9T patent/DE22190069T1/de active Pending
- 2016-05-30 PT PT167298074T patent/PT3303583T/pt unknown
- 2016-05-30 PL PL16729807T patent/PL3303583T3/pl unknown
- 2016-05-30 ES ES16729807T patent/ES2798271T3/es active Active
- 2016-05-30 PL PL22190069.9T patent/PL4108769T3/pl unknown
- 2016-05-30 EP EP20166485.1A patent/EP3744843A1/en active Pending
- 2016-05-30 DK DK16729807.4T patent/DK3303583T3/da active
- 2016-05-30 PT PT221900699T patent/PT4108769T/pt unknown
- 2016-05-30 CN CN201680031561.5A patent/CN107873055B/zh active Active
- 2016-05-30 WO PCT/EP2016/062152 patent/WO2016193206A1/en active Application Filing
- 2016-05-30 US US15/580,092 patent/US10760070B2/en active Active
- 2016-05-30 EP EP16729807.4A patent/EP3303583B1/en active Active
- 2016-05-30 CN CN202111020013.1A patent/CN113897350A/zh active Pending
- 2016-05-30 EP EP22190069.9A patent/EP4108769B1/en active Active
- 2016-05-30 ES ES22190069T patent/ES2960429T3/es active Active
-
2020
- 2020-07-21 US US16/934,279 patent/US11274293B2/en active Active
-
2022
- 2022-02-03 US US17/591,978 patent/US11667910B2/en active Active
- 2022-08-16 US US17/820,242 patent/US11760992B2/en active Active
-
2023
- 2023-05-16 US US18/198,258 patent/US11834651B2/en active Active
- 2023-10-23 US US18/491,943 patent/US12221605B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240247249A1 (en) | 2024-07-25 |
| US11667910B2 (en) | 2023-06-06 |
| PT4108769T (pt) | 2023-10-10 |
| US20220325273A1 (en) | 2022-10-13 |
| EP3744843A1 (en) | 2020-12-02 |
| ES2798271T3 (es) | 2020-12-10 |
| PL4108769T3 (pl) | 2024-02-05 |
| US12221605B2 (en) | 2025-02-11 |
| US11834651B2 (en) | 2023-12-05 |
| US10760070B2 (en) | 2020-09-01 |
| EP4108769A1 (en) | 2022-12-28 |
| WO2016193206A1 (en) | 2016-12-08 |
| CN107873055A (zh) | 2018-04-03 |
| US20180298372A1 (en) | 2018-10-18 |
| US11760992B2 (en) | 2023-09-19 |
| DE202016009003U1 (de) | 2021-05-28 |
| US11274293B2 (en) | 2022-03-15 |
| CN107873055B (zh) | 2021-09-17 |
| DK4108769T3 (da) | 2023-10-09 |
| DK3303583T3 (da) | 2020-07-13 |
| CN113897350A (zh) | 2022-01-07 |
| EP4108769B1 (en) | 2023-08-30 |
| US20230287388A1 (en) | 2023-09-14 |
| ES2960429T3 (es) | 2024-03-04 |
| EP3303583B1 (en) | 2020-04-01 |
| PT3303583T (pt) | 2020-07-07 |
| US20230151352A1 (en) | 2023-05-18 |
| DE22190069T1 (de) | 2023-03-02 |
| EP3303583A1 (en) | 2018-04-11 |
| US20210040473A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3303583T3 (pl) | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym | |
| ZA201706320B (en) | Catalyst for purification of exhaust gas, method for producing the same, and method for purification of exhaust gas using the same | |
| EP3109225A4 (en) | Method for purifying fluid that includes trifluoroethylene, and method for producing trifluoroethylene | |
| PT3180111T (pt) | Elemento de separação por fluxo tangencial integrando obstáculos à circulação e processo de fabricação | |
| SG11201803576SA (en) | Method for wastewater treatment and the treatment system thereof, and method for the preparation of a molecular sieve and the preparation system | |
| GB201420730D0 (en) | Filter, and apparatus and method for filter manufacture | |
| PL3356739T3 (pl) | Układ i sposób filtracji gazu | |
| PT3180109T (pt) | Novas geometrias de elementos tubulares de canais múltiplos destinados à separação por escoamento tangencial e que têm promotores de turbulência integrados e método de fabrico | |
| EP3115095A4 (en) | Honeycomb filter, and method for manufacturing honeycomb filter | |
| PL3452203T3 (pl) | Pierścieniowy element filtrujący, zwłaszcza do filtracji gazów | |
| KR20180084628A (ko) | 백 필터용 여과포 및 그의 제조 방법 및 백 필터 | |
| EP3354336A4 (en) | CATALYST FOR EXHAUST GAS PURIFICATION, PRODUCTION METHOD THEREFOR, AND EXHAUST GAS PURIFICATION APPARATUS COMPRISING SAID CATALYST | |
| ZA201802111B (en) | Method for purifying a voc-laden gas stream | |
| PL3448542T3 (pl) | Element filtracyjny do filtracji gazów odlotowych lub gazów procesowych oraz sposób wytwarzania takiego elementu filtracyjnego | |
| EP3284533A4 (en) | Method of regenerating used denitration catalyst | |
| EP3094525A4 (en) | System and method for inflation gas filtration through a tortuous flow pathway | |
| PL2933018T3 (pl) | Katalizator denitryfikacji, sposób denitryfikacji dymów przy użyciu takiego katalizatora i sposób wytwarzania takiego katalizatora | |
| EP3421127A4 (en) | EXHAUST GAS PURIFYING CATALYST AND METHOD FOR MANUFACTURING THE SAME | |
| PL3394019T3 (pl) | Sposób wytwarzania i oczyszczania 2,3,3,3-tetrafluoropropenu | |
| EP3202479A4 (en) | Method for producing honeycomb filter | |
| SG11202100367PA (en) | Gas purification filter, method for producing gas purification filter, and gas purification system | |
| EP3132841A4 (en) | Exhaust gas purification system, catalyst and exhaust gas purification method | |
| EP3202480A4 (en) | Method for producing honeycomb filter | |
| EP3159058A4 (en) | Exhaust gas purifying catalyst, exhaust gas purification device and filter, and method for producing said catalyst | |
| EP3266520A4 (en) | Conjugated-diolefin-producing catalyst, and production method therefor |